Meropenem Injection 1g (Meropenem Hydrate)

Adult administration

For meropenem hydrate, administer 0.5 to 1 g per day (activity) divided into 2 to 3 doses via slow intravenous infusion for at least 30 minutes. For suspected infections in pathogenic pneumonia, peritonitis, and neutropenic patients with sepsis, administer 1 g (activity) every 8 hours via slow intravenous infusion. For cystic fibrosis and meningitis, administer 2 g (activity) every 8 hours via slow intravenous infusion.

Child administration

For bacterial meningitis in children over 3 months, administer 40 mg per kg body weight via slow intravenous infusion every 8 hours for a minimum of 30 minutes. Additionally

This drug should not be used in patients who have previously experienced shock due to this drug. Additionally, this drug is not to be co-administered with sodium valproate as it may lower valproate blood levels, increasing the risk of recurrent seizures. Patients who have had allergic reactions to this drug or any of its components should not use it. Patients with a history of severe allergic reactions to other carbapenem antibiotics or beta-lactam antibiotics (e.g., penicillins, cephalosporins) should also avoid administration. Patients with allergic constitution or those who frequently experience allergic symptoms such as bronchial asthma and rashes should use this drug cautiously. Patients with reduced kidney function should adjust the dosage or increase the administration interval as this drug can remain in the body longer and may lead to central nervous system side effects. Patients with epilepsy or central nervous system diseases should be cautious as they may have a risk of seizures or consciousness disturbances. Patients with severely impaired liver function require careful administration as their condition may worsen. Elderly patients may have weakened body functions, requiring dose and frequency adjustments while being monitored for side effects. Patients who have difficulty taking orally or who are in poor nutritional status should be monitored closely as they may develop vitamin K deficiency. The safety and efficacy of this drug in infants under 3 months have not been established, thus its use is not recommended. This drug may cause serious allergic reactions such as shock or anaphylaxis, so patients should be closely monitored before and after administration, and the drug should be discontinued immediately if any adverse symptoms occur. If allergy symptoms such as rash, urticaria, or itching appear, administration should be halted, and appropriate treatment should be received. Various blood abnormalities, such as leukopenia, anemia, and platelet abnormalities, may occur, so regular blood tests are necessary and administration should be stopped if abnormalities are detected. Liver dysfunction, acute hepatitis, or liver failure can occur, requiring regular liver function tests and discontinuation of administration if abnormalities are found. There is a risk of rapid deterioration of kidney function, so regular kidney function tests should be conducted and administration should be halted if abnormalities are detected. Severe diarrhea or abdominal pain may indicate a serious colitis such as pseudomembranous colitis, requiring immediate discontinuation and treatment. Central nervous system side effects may cause seizures or consciousness disturbances, thus special caution is necessary when administered to patients with kidney or central nervous system diseases. Respiratory symptoms or severe skin reactions may manifest, so symptoms should be carefully monitored. Muscle-related side effects such as rhabdomyolysis can occur, so immediate notification is needed if muscle pain, weakness, or changes in urine color arise. This drug has many drug interactions, particularly when used with valproate, probenecid, anticonvulsants, contraceptives, warfarin, and requires careful monitoring of blood levels or effects. Women who are pregnant or may become pregnant should use this drug with caution, carefully considering the risks and benefits, and nursing mothers should avoid breastfeeding while receiving this drug. This drug should only be administered intravenously and should be used rapidly after reconstitution, and it is important to use it within the specified timeframe when stored.

Serious side effects

Urticaria, severe swelling (angioedema), chest tightness, difficulty breathing, cold sweat, pallor, shock, anaphylaxis, high fever with severe rash, blistering, skin peeling, pain in mucous membranes of mouth/eyes, severe skin reactions, asthma attacks, breathing difficulties accompanied by cough and fever, pulmonary edema, severe liver dysfunction, jaundice, acute kidney failure, severe renal impairment, severe edema, urinary abnormalities, severe colitis, fulminant hepatitis, seizures, altered consciousness

Mild side effects

• Oral dysgeusia
• dizziness
• changes in stool
• tinnitus
• sweating
• heat sensation
• erythema
• itching
• fever
• redness

This drug should be stored in a sealed container to prevent air entry, at a temperature between 1 to 30 degrees Celsius. Storing it this way helps to maintain the drug's efficacy and prevent deterioration.

Appearance

A crystalline powder that is white to light yellow, contained in a colorless and transparent vial.

Package unit

10 vials/box [1,208 milligrams/vial]